UBS raises Jazz Pharmaceuticals price target to $337
UBS raised its price target on Jazz Pharmaceuticals to $337.00 per share from $315.00, while maintaining a Buy rating.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.